Sanofi Pasteur: COVID-19 Candidate Vaccines

Sanofi Pasteur is Adding a Second Vaccine Approach for COVID-19

1. Baculovirus recombinant vaccine approach
   - Baculovirus recombinant with the gene of interest
   - Baculovirus engineered with the gene of interest
   - Virus does not need to be adapted to grow in eggs or other cell types
   - SF+ cells infected with recombinant virus
   - Incubated for ~48 to 72 hours
   - High yield of protein of interest generated

2. Translate Bio mRNA vaccine approach
   - mRNA: messenger ribonucleic acid; LNP: lipid nanoparticle
   - Different mechanism of action
   - Adds manufacturing capacity
   - Building on current collaboration
   - R&D synergies


4. Sanofi Pasteur is Adding a Second Vaccine Approach for COVID-19

Reference:
- Flublok®, manufactured with this platform and licensed in the U.S.
- Baculovirus recombinant vaccine approach
- BARDA: Biomedical Advanced Research and Development Authority

Coronavirus disease of 2019 (COVID-19) in collaboration with Regeneron and Luminostics

Diagnostics: Smartphone-based self-testing solution

Translation

Formulation

Delivery